Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06748404 · ClinicalTrials.gov registry record · Phase 2
TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus
A Phase 2 study of Immunotherapy-related Pruritus, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT06748404 is a Phase 2 study of Immunotherapy-related Pruritus that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 28 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06748404, a Phase 2 study of Immunotherapy-related Pruritus, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase 2, randomized, open-label, single-center study that will assess the efficacy of TriCalm Hydrogel®, a topical gel containing strontium, for treating pruritus related to immune checkpoint inhibitors (ICIs).
Conditions Studied
Interventions
- DRUG Tricalm Hydrogel
- DRUG Triamcinolone acetonide 0.1% cream
Study Locations (1)
California
- University of California San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-01-31 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06748404
The ClinicalTrials.gov registry entry for NCT06748404 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immunotherapy-related Pruritus appearing as the primary indexed condition, and to 2 interventions - of which Tricalm Hydrogel is the first listed.
NCT06748404 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06748404 about?
NCT06748404 is a clinical study titled "TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus". This is a phase 2, randomized, open-label, single-center study that will assess the efficacy of TriCalm Hydrogel®, a topical gel containing strontium, for treating pruritus related to immune checkpoint inhibitors (ICIs).
What is the current status of trial NCT06748404?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2025-01-31. Estimated completion is 2028-12.
What conditions does trial NCT06748404 study?
This clinical trial studies the following conditions: Immunotherapy-related Pruritus.
What interventions are being tested in trial NCT06748404?
The interventions under investigation include: Tricalm Hydrogel (DRUG), Triamcinolone acetonide 0.1% cream (DRUG).
Who is sponsoring clinical trial NCT06748404?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06748404 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.